Taysha Gene Therapies, Inc. (TSHA) Insider Trading

Over the last 3 months, TSHA insiders made 0 open-market buys and 1 sale, a net sale of -$1.2M (SEC Form 4). Over the last 6 months, 69 institutions increased and 55 reduced their position (13F).

Insider Activity

Sentiment
0/100
Buys (3m)
0
Sells (3m)
1
Net (3m)
-$1.2M
Insider trades by month Buys Sells
Sep
Dec
Jan
Feb
Apr
Jul
Context3-month price +7.6%Institutions reducing (13F)
DateInsiderTypeSharesPrice
Jul 10, 2026Nagendran Sukumardirector, officer: President and Head of R&DSell200,000$6.24
Jun 2, 2026Long Alison SdirectorGrant21,335—
Jun 2, 2026Long Alison SdirectorGrant42,671$5.97
Jun 2, 2026Sepp-Lorenzino LauradirectorGrant21,335—
Jun 2, 2026Sepp-Lorenzino LauradirectorGrant42,671$5.97
Jun 2, 2026Donenberg Phillip B.directorGrant42,671$5.97
Jun 2, 2026Stalfort John A IIIdirectorGrant21,335—
Jun 2, 2026Stalfort John A IIIdirectorGrant42,671$5.97
Jun 2, 2026Donenberg Phillip B.directorGrant21,335—
Apr 13, 2026Nagendran Sukumardirector, officer: President and Head of R&DOption19,021$1.71
Apr 13, 2026Nagendran Sukumardirector, officer: President and Head of R&DSell200,000$4.46
Feb 6, 2026Alam Kamranofficer: CHIEF FINANCIAL OFFICERSell1,655$4.52
Jan 27, 2026Alam Kamranofficer: CHIEF FINANCIAL OFFICERSell23,849$4.61
Jan 27, 2026Nagendran Sukumardirector, officer: President and Head of R&DSell26,918$4.61
Jan 27, 2026Nolan Sean P.director, officer: Chief Executive OfficerSell136,789$4.75
Jan 27, 2026Nagendran Sukumardirector, officer: President and Head of R&DSell89,132$4.75
Jan 27, 2026Nolan Sean P.director, officer: Chief Executive OfficerSell41,312$4.61
Jan 27, 2026Alam Kamranofficer: CHIEF FINANCIAL OFFICERSell78,968$4.75
Jan 14, 2026Nolan Sean P.director, officer: Chief Executive OfficerGrant648,000$4.86
Jan 14, 2026Alam Kamranofficer: CHIEF FINANCIAL OFFICERGrant359,000—
Jan 14, 2026Alam Kamranofficer: CHIEF FINANCIAL OFFICERGrant231,000$4.86
Jan 14, 2026Nolan Sean P.director, officer: Chief Executive OfficerGrant1,008,000—
Jan 14, 2026Nagendran Sukumardirector, officer: President and Head of R&DGrant427,000—
Jan 14, 2026Nagendran Sukumardirector, officer: President and Head of R&DOption88,676$1.71
Jan 14, 2026Nagendran Sukumardirector, officer: President and Head of R&DOption111,324$0.70
Jan 14, 2026Nagendran Sukumardirector, officer: President and Head of R&DSell200,000$4.71
Jan 14, 2026Nagendran Sukumardirector, officer: President and Head of R&DGrant274,000$4.86
Dec 1, 2025Nagendran Sukumardirector, officer: President and Head of R&DOption39,953$1.71
Dec 1, 2025Nagendran Sukumardirector, officer: President and Head of R&DOption70,172$0.70
Dec 1, 2025Nagendran Sukumardirector, officer: President and Head of R&DSell110,125$4.75

Source: TSHA SEC Form 4 filings, latest Jul 10, 2026. For informational purposes only — not investment advice.

Institutional activity (13F)

How institutions changed their TSHA positions over the last 6 months (SEC Form 13F).

Increased
69
New positions
37
Reduced
55
Sold out
192
Largest moves
InstitutionActionSharesFiled
RA CAPITAL MANAGEMENT, L.P.Unchanged23.6MMay 15, 2026
GOLDMAN SACHS GROUP INCReduced22.4MMay 15, 2026
AVORO CAPITAL ADVISORS LLCReduced21.7MMay 15, 2026
AVORO CAPITAL ADVISORS LLCUnchanged21.7MMar 16, 2026
BLACKROCK, INC.Reduced18.4MMay 13, 2026
VESTAL POINT CAPITAL, LPIncreased18.0MMay 15, 2026
MORGAN STANLEYReduced18.0MMay 15, 2026
FMR LLCIncreased14.3MMay 15, 2026
GOLDMAN SACHS GROUP INCIncreased13.7MMar 25, 2026
RTW INVESTMENTS, LPReduced13.7MMay 15, 2026
STATE STREET CORPIncreased11.2MMay 15, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position10.2MMay 15, 2026
OCTAGON CAPITAL ADVISORS LPUnchanged8.9MMay 15, 2026
SIREN, L.L.C.Reduced8.8MMay 14, 2026
POLAR CAPITAL HOLDINGS PLCReduced5.7MMay 15, 2026

Source: SEC Form 13F filings. For informational purposes only — not investment advice.

← Back to TSHA overview (price, financials, earnings)